Author

B. M. Dcosta

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 11 Organism:virus· 4 Organism:human· 3 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

N. R. Landau· 11 shared T. Tada· 11 shared H. Zhou· 9 shared M. J. Mulligan· 7 shared M. I. Samanovic· 6 shared A. Cornelius· 3 shared R. Herati· 2 shared A. Vaill· 1 shared

Activity by Year

2021-2023 · peak 8/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersImmunology

N. R. Landau

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Vectored Immunoprophylaxis and Treatment of SARS-CoV-2 Infection

T. Tada, B. M. Dcosta, J. Minnee, N. R. Landau

This study demonstrates that AAV vectors expressing ACE2 decoy receptors can protect mice against SARS-CoV-2 infection, including recent Omicron subvariants, even when administered post-infection.

bioRxiv · Jan 11, 2023 · PreprintMicrobiology

Prophylaxis and Treatment of SARS-CoV-2 infection by an ACE2 Receptor Decoy

T. Tada, B. M. Dcosta, H. Zhou, N. R. Landau

This study demonstrates that an ACE2 receptor decoy protein effectively reduces SARS-CoV-2 virus loads in mice against both parental and Omicron variants.

bioRxiv · Dec 31, 2022Microbiology

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies

H. Zhou, T. Tada, B. M. Dcosta, N. R. Landau

This study evaluates the neutralization of SARS-CoV-2 Omicron BA.2 by therapeutic monoclonal antibodies, finding reduced neutralization by several antibodies but retention of activity by the AZD8895+AZD1061 cocktail.

bioRxiv · Feb 15, 2022Immunology

Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies

T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, V. Chivukula, R. Herati, S. R. Hubbard, M. J. Mulligan, N. R. Landau

The paper assesses Omicron's resistance to vaccine and monoclonal antibody neutralization, finding boosters improve efficacy but existing therapies are largely ineffective.

bioRxiv · Dec 28, 2021Immunology

Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection

T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, A. Cornelius, R. Herati, M. J. Mulligan, N. R. Landau

This study evaluates neutralization of SARS-CoV-2 Mu and C.1.2 variants by vaccine-elicited and convalescent antibodies, finding that vaccine-induced responses remain protective despite partial resistance.

bioRxiv · Oct 19, 2021Immunology

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

T. Tada, H. Zhou, M. I. Samanovic, B. M. Dcosta, A. Cornelius, M. J. Mulligan, N. R. Landau

This study compares neutralizing antibody titers from mRNA and adenoviral vector vaccines against SARS-CoV-2 variants, finding lower neutralization against variants for Ad26.COV2.S and suggesting a second dose may improve protection.

bioRxiv · Jul 19, 2021Immunology

SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum

T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, M. J. Mulligan, N. R. Landau

This study assesses the neutralization efficacy of convalescent sera and mRNA vaccine-elicited antibodies against the SARS-CoV-2 lambda variant, finding minimal reduction in neutralizing titers.

bioRxiv · Jul 2, 2021 · PreprintImmunology

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.

T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, M. J. Mulligan, N. R. Landau

This study evaluates the neutralization resistance of SARS-CoV-2 B.1.617 and B.1.618 spike proteins to vaccine-elicited and therapeutic antibodies, finding partial resistance due to specific mutations.

bioRxiv · May 14, 2021Immunology

B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies

H. Zhou, B. M. Dcosta, M. I. Samanovic, M. J. Mulligan, N. R. Landau, T. Tada

The paper assesses neutralization of B.1.526 SARS-CoV-2 variants by vaccine-elicited and therapeutic antibodies, finding minimal impact on neutralizing titers.

bioRxiv · Mar 24, 2021Immunology

Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

T. Tada, B. M. Dcosta, H. Zhou, A. Vaill, W. Kazmierski, N. R. Landau

This study evaluates the neutralization activity of two monoclonal antibodies against SARS-CoV-2 variants, finding reduced efficacy against B.1.351 and mink cluster 5 due to specific spike protein mutations.

bioRxiv · Feb 18, 2021 · PreprintImmunology

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

T. Tada, B. M. Dcosta, M. Samanovic-Golden, R. S. Herati, A. Cornelius, M. J. Mulligan, N. R. Landau

This study evaluates the neutralizing activity of convalescent sera and BNT162b2 vaccine antibodies against SARS-CoV-2 variants, showing reduced efficacy against B.1.351 due to E484K mutation but overall maintained protection.

bioRxiv · Feb 5, 2021Microbiology